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In response to DNA damage, cells activate a highly conserved and complex kinase-based
signaling network, commonly referred to as the DNA damage response (DDR), to
safeguard genomic integrity. The DDR consists of a set of tightly regulated events,
including detection of DNA damage, accumulation of DNA repair factors at the site
of damage, and finally physical repair of the lesion. Upon overwhelming damage the
DDR provokes detrimental cellular actions by involving the apoptotic machinery and
inducing a coordinated demise of the damaged cells (DNA damage-induced apoptosis,
DDIA). These diverse actions involve transcriptional activation of several genes that
govern the DDR. Moreover, recent observations highlighted the role of ubiquitylation
in orchestrating the DDR, providing a dynamic cellular regulatory circuit helping to
guarantee genomic stability and cellular homeostasis (Popovic et al., 2014). One of the
hallmarks of human cancer is genomic instability (Hanahan and Weinberg, 2011). Not
surprisingly, deregulation of the DDR can lead to human diseases, including cancer, and
can induce resistance to genotoxic anti-cancer therapy (Lord and Ashworth, 2012). Here,
we summarize the role of ubiquitin-signaling in the DDR with special emphasis on its role
in cancer and highlight the therapeutic value of the ubiquitin-conjugation machinery as a
target in anti-cancer treatment strategy.
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Ubiquitin—Small Molecule Generating a Broad Range of Cellular
Actions
Ubiquitin (Ub) is an essential, highly conserved, 76 residue protein that is ubiquitously
expressed in cells. It can be found either in a free form or covalently attached to a target
protein (Schlesinger et al., 1975; Hershko et al., 1983; Ciechanover et al., 1985; Hershko and
Ciechanover, 1998). Ub acts as a versatile cellular signal that controls a wide range of biolog-
ical processes, including protein degradation, DNA repair, endocytosis, autophagy, transcrip-
tion, immunity and inflammation. Ub, E1-, E2-, and E3-enzymes are successively required to
target a certain substrate for degradation. Ub is attached to specific substrates in a three-
step mechanism, with distinct enzymes catalyzing each step (Figure 1). In a first activating
step, Ub becomes covalently conjugated to the side chain of an E1-cysteine via its carboxy-
terminal (C-terminal) glycine in an ATP-dependent reaction. Activated Ub is then transferred
to an E2-enzyme (ubiquitin-conjugating enzyme) via a thioester-bond between the C-terminal
glycine residue of Ub and an E2 internal cysteine. Finally, Ub-bound E2 interacts with an E3
Ub ligase that catalyzes Ub transfer from E2 to a specific target protein (Ciechanover et al.,
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FIGURE 1 | Ubiquitin conjugation machinery. Ub is attached to specific
substrates in a three-step mechanism, with distinct enzymes catalyzing each
step. First, Ub gets activated by the Ub-activating enzyme (E1). Next, activated
Ub is transferred by one of several dozens of Ub-conjugating enzymes (E2) to
one of approximately 500 substrate-specific Ub-ligases (E3s) that finally
attaches Ub to the substrate (Pickart, 2001). In some cases, the extension of
short ubiquitin chains requires additional elongation factors, termed E4
enzymes. About 100 substrate-specific deubiquitylating enzymes (DUBs)
counteract the activity of UB-conjugating enzymes (Nijman et al., 2005). The
first Ub is either transferred to a ε-NH2 group of a lysine residue (K) of the target
protein to generate an isopeptide bond, or in a linear manner to the N-terminal
residue of the substrate (Breitschopf et al., 1998; Pickart, 2001). Subsequent
Ub addition can occur through isopeptide linkage on all of ubiquitin’s seven
lysine residues as well as its N-terminal primary amino group, thereby
generating a diverse range of chain topologies (Met1-linked, K6, K11, K27,
K29, K33, K48, K63 or mixed) that can drive a variety of different protein fates.
1984; Scheffner et al., 1995; Hershko and Ciechanover, 1998).
This cascade of sequential interactions results in the formation
of an isopeptide bond between the C-terminus of Ub and the ε-
amino group of a lysine residue in the target protein (Hershko
and Ciechanover, 1998). In some cases, the extension of short Ub
chains requires additional elongation factors, called E4 enzymes.
Saccharomyces cerevisiae ubiquitin fusion degradation 2 (Ufd2) is
the first discovered E4 enzyme (Koegl et al., 1999; Hoppe, 2005).
About 100 substrate-specific deubiquitylating enzymes (DUBs)
counteract the activity of Ub-conjugating enzymes (Nijman et al.,
2005). The specificity of Ub signaling is achieved by alternative
conjugation signals (monoubiquitylation and more complex Ub
chains) on alternative substrate sites (Haglund and Dikic, 2005).
Diverse chain topologies can specify a variety of different pro-
tein fates by providing a platform for the interaction with specific
binding partners. These interacting partners depend on Ub bind-
ing domains (UBD) or Ub interacting motifs (UIM) to either
associate with Ub or to decode ubiquitylated target signals into
biochemical cascades (Peng et al., 2003; Komander and Rape,
2012). For instance, monoubiquitylation plays a role in recogniz-
ing DNA double strand breaks (DSBs), K63-linked Ub chains are
involved in the generation of signaling platforms during DNA
repair (Chen et al., 2005a) and polyubiquitin chains covalently
connected via K48 linkages mainly target proteins for degra-
dation by the proteasome (Ciechanover et al., 1984; Thrower
et al., 2000) (Figure 1). The ubiquitin/proteasome system (UPS)
is one of the main regulators of protein stability and—among
multiple cellular pathways—plays an important role in the exe-
cution of the DDR. Multiple studies using proteasome-inhibitors
validated the UPS as a valuable therapeutic target in cancer
(Voges et al., 1999; Orlowski and Kuhn, 2008); however, targeting
one of the major cellular pathways governing protein turnover
may cause broad and unspecific off-target cellular responses.
Accordingly, ongoing efforts aim to identify the specific tar-
gets within the UPS system to selectively target the relevant
Ub-conjugation process. Hence, novel Ub ligases or DUBs are
frequently evaluated as potential specific targets for anti-cancer
therapy.
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Recognition of DNA Damage Sites
Massive Ub accumulation around sites of DNA damage can be
detected as soon as 15 s following the damage event (Feng and
Chen, 2012). Ubiquitylation of the H2A, H2B, and H2AX his-
tone subunits is one of the initial events promoting the destabi-
lization of the nucleosome (Li et al., 1993; Biswas et al., 2011).
CHFR (checkpoint with Forkhead-associated (FHA) and RING
finger domain protein), which is recruited to DSBs by PAR (poly
(ADP) ribose), regulates the first wave of histone ubiquityla-
tion (Wu et al., 2011a). CHFR ubiquitylates PARP1 (PAR poly-
merase 1) via K48- (site K88, E2: UbcH5C) and K63-linked
(E2: Ubc13) Ub chains, and this ubiquitylation is thought to
promote the dissociation of PARP1 from damage sites (Liu
et al., 2013). Epigenetic inactivation of CHFR has been described
in several types of cancer, including breast cancer (Erson and
Petty, 2004), nasopharyngeal carcinoma (Cheung et al., 2005),
colorectal cancer (Toyota et al., 2003), head and neck can-
cer (Toyota et al., 2003), gastric cancer (Satoh et al., 2003),
lung cancer (Mizuno et al., 2002), esophageal cancer (Shibata
et al., 2002), hepatocellular cancer (Sakai et al., 2005) and T-
cell lymphoma (van Doorn et al., 2005). Furthermore, increasing
evidence indicate the regulatory impact of Ub on cancero-
genesis. Monoubiquitylation of H2A by RNF2-BM1, a mem-
ber of the Polycomb repressive complex 1 (PRC1), is thought
to be important for the transcriptional repression by inhibit-
ing of RNA-PolII-elongation (Zhou et al., 2008). Interestingly,
around 15% of H2A has been described to be constitutively
ubiquitylated (Levinger and Varshavsky, 1980). RNF2-BM1 is
also involved in monoubiquitylation of H2AX at K119 and
K120 (E2: UbcH5C), which in turn initiates the recruitment
of the apical PI3K-related kinase ataxia telangiectasia mutated
(ATM) (Pan et al., 2011; Wu et al., 2011a). ATM is a pro-
tein kinase that phosphorylates several key proteins involved
in the DDR. So far, no role for this initial histone ubiquityla-
tion in the recruitment of the functionally related apical kinases
ATR (ATM/Rad3-related kinase) or DNA-PK (DNA-dependent
protein kinase) has been demonstrated. ATM and ATR trans-
duce the most upstream DDR signal by phosphorylating the
checkpoint kinases CHK1/CHK2 and the tumor suppressor pro-
tein p53, resulting in cell cycle arrest to allow time for DNA
repair, or DDIA after prolonged checkpoint activation, respec-
tively (Shiloh, 2003). Even though the main function of DNA-
PK appears to be the induction of cell cycle arrest and DNA
repair, specifically the non-homologous end-joining (NHEJ)
repair pathway, DNA-PK has also been reported to phosphorylate
p53, thus cooperating with ATM/ATR to induce p53-mediated
cell cycle arrest and apoptosis (Kim et al., 1999). Notably, the
ubiquitin-selective segregase Cdc48/p97/VCP, which is a central
regulator of the UPS, influences the DDR by participating in
ubiquitylation and proteasomal degradation of the catalytic sub-
unit of DNA-PK(cs) in eukaryotes (Acs et al., 2011; Meerang
et al., 2011; Dantuma and Hoppe, 2012; Jiang et al., 2013).
Consequently, the interplay of ubiquitylation and phosphory-
lation events regulates the association of several DDR pro-
teins, most prominently p53, with regulatory E3 ligases or
DUBs.
p53—Signal Transducer from DNA Damage
to Cellular Actions
Activated p53 translocates into the nucleus where it induces the
transcription of several target genes involved in cell cycle regu-
lation, DNA repair, and apoptosis, including the pro-apoptotic
molecule BAX (Miyashita and Reed, 1995) and the BH3-only
proteins PUMA (Nakano and Vousden, 2001) and NOXA (Oda
et al., 2000), which are central in initiating DDIA (Figure 2).
Loss of p53 function is described in over 50% of human can-
cers and is frequently associated with a poor patient prognosis
(Hollstein et al., 1994). The mechanisms by which p53 dif-
ferentially triggers cell cycle arrest, senescence, and apoptosis
are far from being completely understood; however, different
post-translational modifications of p53 (e.g., phosphorylation)
have been described that either alter its DNA binding capacity
directly or that control its association with different binding part-
ners, including transcriptional activators and repressors, thereby
affecting the p53-induced transcriptome in response to DNA
damage (Aylon and Oren, 2007). Moreover, it appears that p53
has different affinities toward different p53-responsive elements
and different levels of p53 protein might fine-tune its promoter
choice, thus determining cell fate. Indeed, low p53 levels tend
to favor growth arrest, whereas higher levels trigger apoptosis
(Laptenko and Prives, 2006). p53 protein stability is efficiently
regulated by the UPS and several E3-ligases (Table 1) and DUBs
(Table 2) have been reported as its direct regulators. Not sur-
prisingly, most E3s or DUBs that regulate p53 stability are also
implicated in cancer and further represent promising targets for
anti-cancer therapy.
Regulation of p53 by Ubiquitin Ligases
The E3 ligase MDM2 has been shown to directly target p53
for proteasomal degradation while ATM/ATR-mediated phos-
phorylation of p53 hampers this interaction (Momand et al.,
1992); however, MDM2 only mediates monoubiquitylation of
p53, but not its polyubiquitylation, arguing for the involve-
ment of additional Ub ligases (Lai et al., 2001). Interestingly,
MDM2 is a transcriptional target of p53 and thus acts in a neg-
ative feedback loop. Furthermore, MDM2 itself is also a target
of ATM and ATM-dependent phosphorylation of MDM2 pre-
cedes p53 accumulation in response to DNA damage (Khosravi
et al., 1999). ATM-mediated phosphorylation of MDM2 at S395
induces MDM2 protein destabilization. One major molecule
that has been further implicated in regulating MDM2-mediated
p53 proteolysis is MDMX (MDM4). MDMX activity seems to
be essential for MDM2-mediated p53 proteolysis by convert-
ing MDM2 into an active conformation (Di Conza et al., 2012)
and further stimulating MDM2 ligase activity (Linke et al.,
2008; Wang et al., 2011; Wade et al., 2012). ATM-mediated
MDM2/MDMX phosphorylation disrupts MDM2 oligomeriza-
tion, thereby inactivating MDM2, leading to p53 stabilization
and activation (Cheng and Chen, 2010); however, MDM2 addi-
tionally promotes ubiquitylation and degradation of MDMX in
response to DNA damage, again acting in a negative feedback
loop (de Graaf et al., 2003; Kawai et al., 2003; Pan and Chen, 2003;
Pereg et al., 2005; Xia et al., 2008). Additional studies showed that
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FIGURE 2 | DNA damage-induced apoptotic signaling. The
recruitment of ATM, ATR or DNA-PK to the site of DNA damage is a
central event during DDR signaling. ATM and ATR transduce the DDR
signal by phosphorylation of the checkpoint kinases CHK1/CHK2, which
results in cell cycle arrest and either DNA repair or DDIA (Shiloh, 2003).
Moreover, ATM and ATR are directly responsible for the post-translational
stabilization and thus accumulation of the tumor supressor p53, a key
player in transducing the DDR signal (see below in this figure). ATM
directly phosphorylates p53 at residue S15 (Banin et al., 1998) and
indirectly through the induction of the CHK2 kinase at residue S20 (Shiloh
and Ziv, 2013). Phosphorylation of p53 is believed to be critical for the
stabilization of p53. Activated p53 translocates into the nucleus where it
induces the transcription of several targets involved in cell cycle regulation,
DNA repair or apoptosis, including the pro-apoptotic molecule BAX
(Miyashita and Reed, 1995) and the BH3-only proteins PUMA (Nakano
and Vousden, 2001) and NOXA (Oda et al., 2000) which in turn induce
MOMP either directly or in cooperation with other BH3-only proteins.
Anti-apoptotic Bcl-2-family members inhibit apoptosis by antagonizing the
induction of MOMP. Upon MOMP, multiple pro-apoptotic molecules are
released from the mitochondrial intermembrane space (IMS) to activate
aspartate proteases, called caspases, which ultimately coordinate most of
the hallmarks of apoptosis and cellular self-destruction.
MDM2 generates non-degradative polyubiquitin chains indi-
cating an additional function of MDM2/MDMX-ubiquitylation
other than the previously demonstrated degradative target ubiq-
uitylation (Badciong and Haas, 2002). An additional factor in the
negative feedback loop regulating p53 is the phosphatase Wip1.
Wip1 acts as a gatekeeper in this regulatory loop by dephos-
phorylating and thus stabilizing MDM2, promoting MDM2-
mediated p53 proteolysis (Lu et al., 2007). Elevated expression
of negative regulators of p53-stability is reported for numerous
tumors and is strongly associated with a poor patient prognosis.
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TABLE 1 | E3 ligases involved in DDIA.
E3 ligase Target
MDM2 MDMX (de Graaf et al., 2003; Kawai et al., 2003; Pan and Chen, 2003; Pereg et al., 2005; Xia et al., 2008), p53 (Momand et al., 1992)
COP1 p53 (Dornan et al., 2004a)
ARF-BP1/Mule p53 (Chen et al., 2005b; Zhong et al., 2005; Parsons et al., 2009), ARF-BP1/Mule (Chen et al., 2005b), MCL-1 (Zhong et al., 2005)
PIRH2 p53 (Sheng et al., 2008), CHK2 (Bohgaki et al., 2013), PIRH2 (Logan et al., 2004; Abou Zeinab et al., 2013), p73 (Jung et al., 2011; Wu et al.,
2011c)
Cul4B p53 (Nag et al., 2004; Thirunavukarasou et al., 2014)
E6-AP p53 (Scheffner et al., 1993)
Cul4A-DDB1 p53 (Nag et al., 2004), p73 (Malatesta et al., 2013)
ITCH p63 (Rossi et al., 2006), p73 (Rossi et al., 2005), tBID (Azakir et al., 2010)
SCFFbw7 MCL-1 (Inuzuka et al., 2011; Wertz et al., 2011)
SCFβTrCP MCL-1 (Ding et al., 2007), BIM (Dehan et al., 2009)
APC/Cdc20 MCL-1 (Harley et al., 2010)
TRIM17 MCL-1 (Magiera et al., 2013)
SAG/RBX2 BIM (Li et al., 2014)
TRIM2 BIM (Thompson et al., 2011)
Culin/ElonginB-CIS BIM (Ambrosini et al., 2009)
RNF186 BNip1 (Wang et al., 2013)
TABLE 2 | DUBs involved in DDIA.
DUB Target
USP7 p53 (Li et al., 2002), ARF-BP-1/Mule (Khoronenkova and Dianov,
2013)
USP4 ARF-BP-1/Mule (Zhang et al., 2011)
USP2a MDM2 (Stevenson et al., 2007), MDMX (Allende-Vega et al., 2010)
USP10 p53 (Yuan et al., 2010)
USP42 p53 (Hock et al., 2011)
USP29 p53 (Liu et al., 2011)
UCH-L1 ∗p53 (Li et al., 2010; Xiang et al., 2012), NOXA (Brinkmann et al.,
2013)
Otubain 1 ∗p53 (Sun et al., 2012)
USP9X MCL-1 (Schwickart et al., 2010)
USP18 *BIM (Santin et al., 2012)
*Indirect stabilization, no direct deubiquitylation reported.
For instance, elevated expression of MDM2 has been identified
in breast cancer (Bueso-Ramos et al., 1996), leukemias (Bueso-
Ramos et al., 1993), and in lung cancer (Dworakowska et al.,
2004). Gene amplifications of MDM2 have been described in 7%
of tumors of diverse origin, with the highest frequency observed
in soft tissue tumors, osteosarcomas and esophageal carcinomas
(Momand et al., 1998). MDM2 is also a substrate for alterna-
tive splicing and the production of aberrantly spliced MDM2
RNA is associated with a shortened overall survival of cancer
patients (Bartel et al., 2002). Remarkably, a functional interac-
tion of p53/MDM2 is dispensable for embryonic development,
whereas it is essential for DDIA, thus emphasizing the potential
of the p53/MDM2-interaction as a target in anti-cancer therapy
(Zhao et al., 2013).
The E3 ligase COP1 regulates p53 stability in an
ATM-dependent manner (Dornan et al., 2004a). Upon DNA
damage, activated ATM phosphorylates COP1 on S387 which
in turn stimulates a rapid autodegradation mechanism of COP1
resulting in p53 stabilization (Dornan et al., 2006). COP1 itself
is a transcriptional target of p53, thus representing yet another
feedback loop for controlling p53 stability (Dornan et al., 2004a).
Overexpression of COP1 has been observed in breast cancer
(Dornan et al., 2004b), ovarian adenocarcinoma (Dornan et al.,
2004b), gastric cancer (Li et al., 2012; Sawada et al., 2013), and
in hepatocellular carcinoma (Lee et al., 2010) and this high
expression is mostly associated with a poor prognosis.
p53 stability is also negatively controlled by ARF-BP1/Mule
encoded by the Huwe1 gene, which is a binding partner of the
alternative binding frame (ARF) tumor suppressor (Chen et al.,
2005b; Zhong et al., 2005; Parsons et al., 2009). ARF-BP-1/Mule
activity is limited by self-ubiquitylation and subsequent protea-
somal turnover (Chen et al., 2005b). Increased ARF-BP1/Mule
degradation causes p53 stabilization, which is antagonized by
the DUBs USP7 (Khoronenkova and Dianov, 2013) and USP4
(Zhang et al., 2011). ARF-BP1/Mule was found to be expressed
at high levels in lymphoma cell lines (Qi et al., 2012) and in col-
orectal and breast cancer cells (Xie et al., 2002) and it promotes
Myc-driven tumorigenesis (Qi et al., 2012), whereas it suppresses
Ras-driven tumorigenesis (Inoue et al., 2013).
Another specific E3 ligase for p53 is PIRH2, which was ini-
tially named p27(Kip1) and implicated in cell cycle regulation
(Leng et al., 2003). Remarkably, PIRH2 preferentially ubiquity-
lates the transcriptional active form of p53 (Sheng et al., 2008).
Moreover, PIRH2 also regulates the stability of the effector kinase
CHK2 (Bohgaki et al., 2013) and phosphorylation of PIRH2 by
calmodulin-dependend kinase 2 impairs its ability to ubiquity-
late p53 (Duan et al., 2007). Again, PIRH2 levels are regulated by
self-ubiquitylation following proteasomal turnover (Logan et al.,
2004; Abou Zeinab et al., 2013). PIRH2 is overexpressed in a
variety of tumor cells including hepatocellular carcinoma (Wang
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et al., 2009; Hu et al., 2012), head and neck cancers (Shimada
et al., 2009), clear renal cell carcinoma (Wu et al., 2013), lung
cancer (Duan et al., 2004), and prostate cancer (Logan et al.,
2006).
A number of additional E3 ligases are reported to regulate p53
degradation, including Cul4B (Thirunavukarasou et al., 2014),
E6-AP (Scheffner et al., 1993), and Cul4A-DDB1 (Nag et al.,
2004; Thirunavukarasou et al., 2014). Strikingly, regulation of
p53 protein is also influenced by the activities of the E4 lig-
ases UBE4B/UFD2a/Ufd2 (Wu et al., 2011b) and CBP (CREB-
binding protein)/p300 (E1A binding protein p300) (Shi et al.,
2009).
E4 ligases mediate the polyubiquitylation of specific
monoubiquitylated substrate proteins, including p53. Recently,
CBP and p300 were identified to possess E4 activity and can
elongate monoubiquitylated p53 into the cytosolic polyubiqui-
tylated form (Shi et al., 2009). In addition, the E4 ligase UBE4B
interacts physically with p53 and MDM2 to polyubiquitylate
p53 (Wu et al., 2011b). Consequently, elevated levels of UBE4B
are linked to brain tumors and medulloblastoma cell lines. It
was further observed that the gene locus of UBE4B (1p36.22)
is a susceptible candidate locus for hepatitis B virus (HBV)
related hepatocellular carcinoma (HCC), forming a possible
link between UBE4B/UFD2 and cancer development and tumor
suppression (Zhang et al., 2010; Wu and Leng, 2011; Wu et al.,
2011b).
Regulation of p53 by DUBs
So far, several DUBs are known to regulate p53 stability, either
directly by deubiquitylation and stabilization of p53 itself, or by
regulating its key regulators or binding partners. The ubiquitin-
specific protease USP7 (HAUSP—herpes virus associated USP)
was initially found to be a specific DUB of p53 and its activity sta-
bilizes p53 protein (Li et al., 2002). However, whereas decreased
USP7 expression levels had the expected effect of destabilizing
p53, ablation of USP7 expression was found to have the opposite
effect, resulting in p53 stabilization (Sheng et al., 2006). This p53
stabilization seems to result from increased ubiquitylation and
destabilization ofMDM2, the E3 ligase largely responsible for p53
ubiquitylation (Cummins and Vogelstein, 2004; Li et al., 2004;
Meulmeester et al., 2005). USP2a has been described as a specific
DUB of MDM2 (Stevenson et al., 2007) and MDMX (Allende-
Vega et al., 2010) and thereby acts as a negative regulator of
p53 stability. USP10 is a cytosolic DUB that specifically deubiq-
uitylates p53, while ATM-mediated phosphorylation results in
USP10 stabilization as well as nuclear translocation, resulting in
p53 stabilization (Yuan et al., 2010). USP42 and USP29 are DUBs
for p53 and improve p53 stability under stress conditions (Hock
et al., 2011; Liu et al., 2011). Similarly, positive regulation of p53
stability has also been described for OTUB1 (Otubain1), which
stabilizes p53 indirectly and independently of its catalytic activ-
ity by binding the E3 ligase MDM2. This interaction inhibits the
cooperation betweenMDM2 andUbcH5s, the E2 enzyme impor-
tant for MDM2-mediated p53 ubiquitylation (Sun et al., 2012).
UCH-L1 has also been reported to regulate p53 protein stability
(Li et al., 2010; Xiang et al., 2012); however, the molecular details
are yet not clear.
Examples for DUBs that might antagonize E4 dependent
polyubiquitylation are USP47, a regulator of Base Excision Repair
(BER) that controls DNA polymerase β andOTUB1, whichmedi-
ates DNA damage-dependent deubiquitylation of p53/MDM2 in
the cytoplasm (Parsons et al., 2011; Sun et al., 2012).
Regulation of the p53 Homologs p63 and p73 by
Ubiquitin Ligases
Interestingly, p53 is required for the DDR in certain but not all
cell types (Clarke et al., 1993; Lowe et al., 1993; Strasser et al.,
1994). Even though the primary role is exerted by p53 itself, the
p53 homologs p63 and p73 can substitute for the downstream
activities of p53. p63 and p73 share 60% similarity with the p53
DNA binding domain, allowing them to transactivate some of the
same target genes. Like p53, p73 proteasomal turnover is regu-
lated by the E3 ligase PIRH2 (Jung et al., 2011; Wu et al., 2011c)
and also by the E4 ligase UFD2a (Hosoda et al., 2005). Further-
more, p63 and p73 protein stability are directly regulated by the
ubiquitin ligase ITCH (Rossi et al., 2005, 2006). p73 is a substrate
of the Cul4A-DDB1 Ub ligase complex which monoubiquitylates
p73 thereby reducing its transcriptional activity without affect-
ing its turnover (Malatesta et al., 2013). MDM2 also binds p73
without supporting its degradation (Balint et al., 1999). Likewise,
MDMX, but not MDM2, has been shown to regulate p63 transac-
tivation potential by inhibiting p63 nuclear localization (Kadakia
et al., 2001).
DNA Repair Mechanisms
DSB repair is mediated by two extensively studied major repair
pathways that have evolved in eukaryotic cells (Chapman et al.,
2012). The error prone NHEJ pathway reunites free DNA ends
at DSBs with little or no sequence homology and is respon-
sible for most of the repair events in eukaryotes (Lemmens
and Tijsterman, 2010). Repair via NHEJ can be rather inexact
because the rejoining of non-complementary DNA ends is sub-
ject to end-processing by the nuclease activity of Artemis and
DNA-PK(cs), which remove damaged ormismatched nucleotides
(Bunting and Nussenzweig, 2013). Accurate ligation depends
on the presence of loose complementary cohesive DNA ends
and is mediated by the NHEJ repair proteins Ku70/80 and
XRCC4-Ligase IV (Dahm-Daphi et al., 2005; Moynahan and
Jasin, 2010). A second repair pathway is homologous recombi-
nation (HR), which dominates in highly proliferative somatic
cells in S- and G2-phase. HR is a high fidelity repair path-
way that relies on recombination between undamaged sister
chromatids or homologous chromosomes (Clejan et al., 2006).
Ubiquitylation of substrate proteins plays an important role
in specifying the use of a specific DNA repair pathway, as
differential ubiquitylation leads to orchestrated recruitment of
specific repair factors such as p53-binding protein 1 (53BP1)
or Breast Cancer Susceptibility Gene 1 (BRCA1) (Jackson and
Durocher, 2013). 53BP1 accumulation promotes NHEJ activa-
tion and HR inhibition, whereas BRCA1 recruitment triggers
HR (Yun and Hiom, 2009). Their recruitment to chromatin sur-
rounding DSB sites is controlled by the action of the RING-
finger protein RNF8, which acts as a central E3 ligase in DDR
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and exhibits two distinct roles: it catalyzes the ubiquitylation
of substrate proteins either via a protein-recruiting K63- or via
a destabilizing K48 specific linkage (Lok et al., 2012). Upon
DNA damage RNF8 detects motifs in mediator of DNA dam-
age checkpoint protein 1 (MDC1) previously phosphorylated
by ATM and performs K63-linked monoubiquitylation of his-
tones H2A and H2AX. Histone monoubiquitylation promotes
RNF8-dependent recruitment of a second E3 ligase, RNF168,
to the damage site, which can identify ubiquitylated RNF8 sub-
strates via its Nterminal ubiquitin-binding domains (Mailand
et al., 2007; Doil et al., 2009). Subsequently, polyubiquityla-
tion of H2AX further promotes the recruitment of RNF168 to
the damage site, amplifying RNF8-dependent histone ubiquity-
lation by ubiquitylating other substrate proteins via K63 (Doil
et al., 2009; Ramadan and Meerang, 2011). The outcome of
RNF8/RNF168-dependent K63-linked ubiquitylation is the gen-
eration of a molecular landing platform for the accumulation
of checkpoint and DNA repair proteins like BRCA1 or 53BP1;
however, 53BP1 itself cannot directly bind to K63 polyubiqui-
tin chains since it lacks any relevant binding site (Al-Hakim
et al., 2010). Therefore, other mechanisms for 53BP1 recruit-
ment are necessary. For example, 53BP1 accumulation is pro-
moted by p97 segregase activity that removes the polycomb
protein L3MBTL1 from DNA DSBs. p97 binds to ubiquitylated
L3MBTL1 and extracts it from chromatin. The displacement
of L3MBTL1 unmasks 53BP1 binding sites that can now be
occupied (Acs et al., 2011).
In addition, RNF8 also ubiquitylates K48-dependent sub-
strates such as the lysine demethylase JMJD2A (Mallette et al.,
2012), the NHEJ repair protein Ku80 (Feng and Chen, 2012),
and the DNA polymerase sliding clamp proliferating cell nuclear
antigen (PCNA), which is involved in DNA synthesis and repair
(Zhang et al., 2008). Consequently, these proteins are removed
from chromatin for proteasomal degradation.
In accordance with the postulated molecular switch model
of PCNA, E4-mediated polyubiquitylation might alter ubiquitin-
dependent signaling fates upon damage induction, possibly
in a cell type specific manner (Hoppe, 2005). This regu-
latory mechanism thereby provides another layer of regula-
tion to fine-tune the highly dynamic cascade of ubiquitylation
events during the DDR, which can also be reversed by DUB
activity.
Besides K48-linked ubiquitylation, PCNA undergoes a switch
mechanism from amono- to a polyubiquitylated form at position
K164, regulating its activity in DNA repair (Hoege et al., 2002).
This modification triggers translesion synthesis (TLS), i.e., DNA
synthesis across lesions. In addition, other factors are needed
to extend the modification by a K63-linked polyubiquitin chain
leading to an error-free pathway of damage avoidance (Hoege
et al., 2002; Daigaku et al., 2010).
A different ubiquitin chain linkage was reported for the E3
ubiquitin ligase BRCA1, which exhibits tumor-suppressor activ-
ities and is crucial for maintaining genomic integrity. As a het-
erodimer with its binding partner BARD1 it specifically catalyzes
the formation of K6-linked polyubiquitin chains on substrates,
such as RNA Polymerase II and γ-Tubulin (Wu-Baer et al., 2003;
Irminger-Finger and Jefford, 2006).
DDIA
In addition to the activation of DNA repair, multicellular organ-
isms acquired a dynamic safe-guard system involving the apop-
totic response to dispose of damaged cells when the extent of
damage is beyond the cellular repair capacity (Levine et al., 1997).
The decision whether a cell survives or dies upon DNA dam-
age is not yet completely understood, however, as mentioned
above, the level of p53 abundance is a key factor in the cellular
decision of life or death in response to DNA damage. Similarly,
the quality of p53 downstream death signaling—the induction
of intrinsic/mitochondrial apoptosis—plays a crucial role in the
coordinated cellular death upon DNA damage. Specifically, the
expression level of pro- and anti-apoptotic proteins, in partic-
ular, members of the Bcl-2-family (see below), is decisive for
the outcome of the DDR signaling. Furthermore, the nature of
the DNA damage, the physiologic status and the origin of the
damaged cell may impact on cellular responses to DNA damage.
For instance, thymocytes are highly primed to undergo DDIA,
whereas primary fibroblasts appear to resist DDIA (Norbury
and Zhivotovsky, 2004). Indeed, the capability of the apoptotic
machinery in immune cells is central during the cellular differ-
entiation of this tissue. For instance, almost 90% of pre-T- and
B-cells undergo apoptosis during maturation. Further, apoptosis
triggers the shutdown of the immune response when infection
has been overcome (Brinkmann and Kashkar, 2014). In conclu-
sion, several cell types are primed for a rapid induction of apop-
tosis which is achieved by a “close-to-death” composition of pro-
and anti-apoptotic proteins, in particular, Bcl-2-family members
(Letai et al., 2002).
Nevertheless, a tight regulation of the response to DNA dam-
age is obligatory in germ cells and somatic cells. In germ cells,
mechanisms for limiting genome alterations are required for
faithful propagation of the species, whereas in somatic cells,
responses to DNA damage prevent the accumulation of muta-
tions that might lead to altered cellular homeostasis.
Bcl-2 Protein Family—Regulators of
Mitochondrial Apoptosis
Mitochondria represent a central regulatory node in the apop-
totic machinery through the mitochondrial outer membrane
permeabilization (MOMP) as the decisive event. Upon MOMP,
multiple pro-apoptotic molecules, including cytochrome C are
released from the mitochondrial intermembrane space (IMS)
to activate aspartate proteases, called caspases, which ultimately
coordinate most of the hallmarks of apoptosis and cellular
self-destruction. Specifically, cytosolic cytochrome C forms a
complex, the apoptosome, with ATP, APAF1, and pro-caspase
9 (pro-casp9), resulting in the activation of caspase 9 (casp9).
Casp9 activates the downstream executioner caspase 3 (casp3)
which ultimately lead to apoptosis.
Inefficient MOMP has been suggested to be one of the key
determinants of therapeutic success of a number of anti-cancer
regimens in cancer patients (Adams and Cory, 2007) and mem-
bers of the Bcl-2 protein family are the key-regulators of this pro-
cess. The Bcl-2 protein family comprises three classes of member.
The first group consists of the anti-apoptotic Bcl-2 protein family
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members, including BCL-2, BCL-xl, BCL-w, A1, andMCL-1, that
efficiently inhibit MOMP and block apoptosis. The second group
consists of pro-apoptotic members such as BAK, BAX, and BOK,
trigger apoptosis by directly promoting MOMP. A third diver-
gent class of BH3-only proteins including BIM, BID, PUMA,
BAD, and NOXA regulates the activity of pro-and anti-apoptotic
Bcl-2 proteins (Adams and Cory, 2007) (Figure 2).
Members of the Bcl-2 protein family share at least one con-
served Bcl-2 homology domain (BH domain), which is charac-
terized by several α-helical segments. The BH domain does not
possess enzymatic activity but it allows pro- and anti-apoptotic
members to bind to and to inhibit each other (Adams and Cory,
1998; Cory and Adams, 2002). Binding affinity assays using BH3-
only peptides revealed that not all pro- and anti-apoptotic Bcl-2
proteins can antagonize each other, but the affinity differs within
the family. The BH3-only proteins BIM, BID, PUMA, and BMF
can bind and antagonize all anti-apoptotic Bcl-2 proteins. In con-
trast, BAD can only bind BCL-2, BCL-xl and BCL-w, and NOXA
is restricted in binding to MCL-1 and A1. To date, there are two
proposed models that explain how the Bcl-2 protein family regu-
lates MOMP: (i) the indirect activator model and (ii) the direct
activator-derepressor model. Both models result in the activa-
tion of BAX and BAK and the permeabilization of the outer
mitochondrial membrane. The indirect activator model postu-
lates that BAX and BAK are bound in a constitutively active state
to anti-apoptotic Bcl-2 proteins. Competitive interactions with
pro-apoptotic BH3-only proteins and anti-apoptotic Bcl-2 pro-
teins are sufficient to release active BAX and BAK and induce
MOMP. In the direct activator-derepressor model (also called
neutralization model), BAX and BAK are activated by the inter-
action with a subset of BH3-only proteins, such as BID and BIM,
called direct activators. In this model, anti-apoptotic Bcl-2 pro-
teins either inhibit MOMP by antagonizing BAX or BAK directly
or by sequestering the direct activator BH3-only proteins, thus
preventing them from activating BAX or BAK. A second sub-
set of BH3-only proteins, called sensitizers, such as NOXA or
BAD, cannot directly activate BAX or BAK but antagonize anti-
apoptotic Bcl-2 proteins and thereby release BAX and BAK for
the activation by direct activator BH3-only proteins (Tait and
Green, 2010).
In response to DNA damage activated p53 translocates
into the nucleus where it induces transcription of several
pro-apoptotic Bcl-2 proteins, including BAX (Miyashita and
Reed, 1995), PUMA (Nakano and Vousden, 2001), and NOXA
(Oda et al., 2000), which in turn induce MOMP. The tran-
scriptional upregulation of these pro-apoptotic members in
response to DNA damage however may not suffice the required
pro-apoptotic trigger toward MOMP as this process is tightly
regulated by a number of other Bcl-2 members and only the ulti-
mate pro-apoptotic composition of these proteins can efficiently
induce cell death (Ni Chonghaile and Letai, 2008). Accordingly,
the genes of some BH3-only proteins appear to be constitutively
transcribed in cancer cells as reported for BIK or NOXA (Hur
et al., 2004; Brinkmann et al., 2013; Dengler et al., 2014). The
majority of these cells however resist apoptosis suggesting that
the imbalance in Bcl-2 protein family members (e.g., upregula-
tion of anti-apoptotic members or downregulation of BAX/BAK)
efficiently counter the pro-apoptotic action of these factors. More
strikingly, non-transcriptional regulation of Bcl-2 protein family
members turn-over was repeatedly shown to control the apop-
totic process under physiological or pathological condition. This
enables cells to rapidly respond to stress cues by regulating
protein abundance without employing protein de novo synthesis.
The clinical successes of proteasome inhibitors for the treat-
ment of cancer have highlighted the therapeutic potential of tar-
geting cellular process governing protein turn-over. Strikingly,
the expression levels of a number of Bcl-2 protein family mem-
bers including NOXA (Qin et al., 2005; Brinkmann et al., 2013),
MCL-1 (Adams and Cory, 2007), A1 (Kucharczak et al., 2005),
BCL-2 (Dimmeler et al., 1999), BAK (Qin et al., 2005), BIK (Mar-
shansky et al., 2001; Hur et al., 2004), BIM (Nikrad et al., 2005)
was altered when the proteasome was inhibited indicating an
essential role of the UPS in regulating Bcl-2-family protein abun-
dance. However, a direct regulation of Bcl-2-protein level via the
UPS has only been reported for BAX (Chang et al., 1998; Li and
Dou, 2000), BIM (Akiyama et al., 2003), BCL-2 (Dornan et al.,
2004b), NOXA (Brinkmann et al., 2013), MCL-1 (Zhong et al.,
2005), A1 (Kucharczak et al., 2005), and BCL-B (van de Kooij
et al., 2013), while the identities of the responsible E3 ligases and
DUBs are largely unknown with some exceptions (Tables 1, 2).
Previous data showed that the stability of the anti-apoptotic
BCL-2 protein is regulated through ubiquitylation which is in
turn controlled by its phosphorylation (Breitschopf et al., 2000a;
Basu andHaldar, 2002). Specifically, MAP kinase-mediated BCL-
2 phosphorylation was shown to block BCL-2 ubiquitylation and
proteasomal degradation (Dimmeler et al., 1999). Furthermore,
BCL-2 turn-over is inhibited by its direct S-nitrosylation (Azad
et al., 2006; Chanvorachote et al., 2006). These data showed
that BCL-2 undergoes S-nitrosylation by endogenous nitric oxide
(NO) in response to multiple apoptotic stimuli. S-nitrosylation of
BCL-2 in turn inhibits its proteasomal degradation.
The level of MCL-1 protein is regulated by the action of
at least five distinct E3-ligases, namely ARF-BP1/Mule (Zhong
et al., 2005), SCFFbw7 (Inuzuka et al., 2011; Wertz et al., 2011),
SCFβTrCP (Ding et al., 2007), APC/Cdc20 (Harley et al., 2010),
Trim17 (Magiera et al., 2013), and the DUB USP9X (Schwickart
et al., 2010). Whether different E3-ligases are engaged in dif-
ferent cellular action and in response to different stimuli is not
determined. Independently, ubiquitylation of MCL-1 has been
mainly considered as a regulatory circuit controlling its abun-
dance. Not surprisingly, dysregulation of MCL-1 ubiquitylation
and turn-over have been repeatedly associated with cancer and
cancer chemoresistance (Schwickart et al., 2010; Wertz et al.,
2011). Mule-dependent MCL-1 ubiquitylation is enhanced by
NOXA, which targets Mule to MCL-1 and competes with USP9X
in MCL-1 binding (Gomez-Bougie et al., 2011). These data sug-
gest that NOXA, in addition to the functional antagonization
of MCL-1, controls MCL-1 turn-over by regulating the physical
interaction of MCL-1 with ubiquitin conjugation/deconjugation
machinery.
Independent of its own inherent pro-apoptotic activity, the
critical role of NOXA in regulating MCL-1 is a unique property
of this protein among other BH3-only protein family members.
NOXA was initially identified as a primary p53-responsive gene,
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providing the first evidence for the transcriptional regulation of
NOXA in response to genotoxic stress (Oda et al., 2000). In addi-
tion to transcriptional regulation, NOXA stability is controlled
by post-translational mechanisms. In particular, ubiquitylation
of NOXA has recently been shown to be involved in the regula-
tion of NOXA protein turn-over and thereby influences cellular
stress responses (Baou et al., 2010; Dengler et al., 2014). Interfer-
ing with this process, dysregulation of NOXA ubiquitylation has
been shown to be an efficient strategy of some tumor cells in order
to resist the genotoxic chemotherapy (Brinkmann et al., 2013).
Specifically, these data showed that NOXA was strongly ubiqui-
tylated in some tumor samples. The elevated NOXA ubiquity-
lation and reduced stability was a result of epigenetic silencing
of NOXA-specific DUB, UCH-L1, which directly deubiquitylates
and stabilizes NOXA (Brinkmann et al., 2013). Furthermore,
NOXA can be degraded by an ubiquitin-independent mecha-
nism suggesting that the disruption of 26S proteasome func-
tion by various mechanisms triggers the rapid accumulation of
NOXA based on the capability of NOXA to act as a sensor of 26S
proteasome integrity (Craxton et al., 2012).
Ubiquitin-dependent degradation of BIM is regulated by
the E3 ligases SAG/RBX2 (Li et al., 2014), TRIM2 (Thompson
et al., 2011), Cullin/ElonginB-CIS (Ambrosini et al., 2009), and
SCFβTrCP (Dehan et al., 2009) while phosphorylation through dif-
ferent kinases including ERK1/2, MAPK and the cell cycle kinase
Aurora A precedes its turnover (Ley et al., 2003; Ramesh et al.,
2008; Dehan et al., 2009; Wiggins et al., 2010). USP18 has also
been shown to be involved in regulating the stability of BIM
upon cytokine-induced cell death. Specifically, USP18 inhibition
in INS-1E cells enhanced BIM expression level in untreated and
IFNγ-treated conditions (Santin et al., 2012).
Analysis of BAX stability in human prostate adenocarcinoma
showed that BAX is highly instable and the reduced BAX protein
levels was associated with increased Gleason scores of prostate
cancer (Chang et al., 1998; Li and Dou, 2000). These results iden-
tified the UPS-mediated BAX degradation as a novel survival
mechanism in tumor cells and suggested that a selective targeting
of this pathway should provide a unique approach for treatment
of human cancers, especially those overexpressing BCL-2 (Chang
et al., 1998; Li and Dou, 2000).
The stability of the BH3-only protein BNip1 is regulated via
the action of the E3 ligase RNF186. BNip1 co-localizes with
RNF186 at the ER and is poly-ubiquitylated by RNF186 through
K29 and K63 linkage in vivo. This modification promotes BNip1
transportation to mitochondria but has no influence on its pro-
tein level (Wang et al., 2013).
Extrinsic apoptotic cascade results in the proteolytic activa-
tion of BID by caspase-8 (Luo et al., 1998). The COOH-terminal
cleavage fragment of BID (truncated BID, tBID) becomes local-
ized to mitochondrial membranes and triggers the release of
cytochrome c. Truncated BID was shown to be ubiquitylated and
subsequently degraded by the 26 s proteasome which is believed
to control the extent of apoptosis in living cells (Breitschopf et al.,
2000b). Further analyses identified the ubiquitin ligase ITCH, as
a specific ubiquitin ligase of tBID which was not able to use intact
BID as a substrate and initiate its proteasomal degradation (Aza-
kir et al., 2010). The N-terminal cleavage product of BID has also
been shown to be a substrate of unconventional ubiquitylation
and degradation as the acceptor site are neither lysines nor N-
terminus (Tait et al., 2007). Acceptor sites reside predominantly
but not exclusively in helix 1, which is required for ubiquitylation
and degradation of tBID-N. Rescue of tBID-N from degradation
blocked BID’s ability to induce mitochondrial outer membrane
permeability but not mitochondrial translocation of the cleaved
complex.
The increasing number of ubiquitin-conjugation events, reg-
ulating the abundance or function of Bcl-2 protein family mem-
bers, is a strong indication of the central role of Ub in DDIA
and provides at the same time a promising therapeutic target for
cancer treatment.
Exploiting Ubiquitin-Signaling in DDR as a
Therapeutic Target in Cancer
The ultimate central goal of conventional cancer therapy is the
effective elimination of tumors by invoking DDIA. Since the bal-
ance of protein abundance and functionality are decisive for DDR
outcomes, it is not surprising that deregulation of ubiquitin-
signaling pathways is intimately associated with tumorigenesis
and therapy resistance. Accumulating recent evidence conclu-
sively identified ubiquitin-signaling as a valuable target in DDR
and cancer chemoresistance. Themajority of these efforts focused
on the regulation of p53 as one of the central determinants of
DDR outcomes. Accordingly, an increasing number of specific
regulators of p53 have been identified and evaluated as thera-
peutic targets. RITA (reactivation of p53 and induction of tumor
cell apoptosis) is a small molecule that blocks p53/MDM2 inter-
action (Issaeva et al., 2004); however, it appeared to be rather
unspecific since its pro-apoptotic capacity was described to be
p53-independent in several tumors, including myelomas (Sur-
get et al., 2014) and additional data indicated that RITA cannot
inhibit this interaction in vitro (Krajewski et al., 2005). Nutlins
are also described to block the interaction of p53 and MDM2
(Vassilev, 2004). These molecules activate the p53 pathway and
suppress tumor growth in vitro and in vivo in tumor xenograft
models of solid and hematologic tumors (Vassilev et al., 2004;
Tovar et al., 2006; Sarek and Ojala, 2007). MI-63 and MI-219 are
small molecules also designed to block the interaction between
p53/MDM2 and early preclinical evaluations demonstrated p53-
mediated cell cycle arrest or apoptosis in tumor xenograft models
upon treatment with Mi-219 (Shangary et al., 2008). P28 is a pep-
tide fragment derived from azurin, a redox protein secreted from
Pseudomonas aeruginosa, which stabilizes p53 by blocking its
interaction with COP1 (Yamada et al., 2013a,b). The first preclin-
ical trials demonstrated inhibition of tumor growth in xenograft
models of p53 positive solid tumors (Jia et al., 2011).
Conclusion
Tumor cell resistance to genotoxic chemotherapy poses a signif-
icant challenge in the treatment of cancer patients. As already
discussed, protein ubiquitylation is central to the orchestra-
tion of the DDR and impacts on susceptibility to conventional
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genotoxic chemotherapy. Recent studies using proteasome-
inhibitors validated the UPS as a therapeutic target in can-
cer and provided an impetus to promote the development of
effective novel drugs that more specifically interfere with the
ubiquitin-conjugating machinery. Thus, a better understand-
ing of the specific link between the DDR and the ubiquitin-
conjugating machinery will undoubtedly identify novel targets
involved in cancer and will promote the development of new
therapeutic strategies to overcome cancer chemoresistance. In
line with this notion, based on its ability to inhibit apop-
tosis, the Bcl-2 protein family has garnered the most atten-
tion as a promising therapeutic target in cancer. Accordingly,
efforts have lately been focused on the development of drugs
targeting Bcl-2 proteins with considerable therapeutic success
(Brinkmann and Kashkar, 2014). In view of the fact that the
acquired imbalance of Bcl-2 proteins is involved in cancer
together with our increasing knowledge about the central role
of ubiquitin-conjugation governing Bcl-2 abundance and func-
tion support the idea that cancer-treatment may strongly benefit
from novel therapeutic protocols targeting ubiquitin-regulation
of Bcl-2 family.
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